Placeholder Banner

BIO President & CEO Jim Greenwood to Testify at Congressional Hearing on Combatting Biological Threats

February 11, 2016

Washington, D.C. (February 11, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood will testify tomorrow at a hearing of the House Energy & Commerce Subcommittee on Oversight and Investigations, "Outbreaks, Attacks, and Accidents: Combating Biological Threats.” Greenwood, who serves on the Blue Ribbon Study Panel on Biodefense, will be joined by fellow panelist Donna Shalala, former Secretary of the Department of Health and Human Services. The Blue Ribbon Study Panel on Biodefense issued a detailed report in October 2015, A National Blueprint for Biodefense: Leadership and Major Reform Needed to Optimize Efforts. Greenwood and Shalala will be joined by Dr. Tara O’Toole of In-Q-Tel and Dr. Gerald Parker of Texas A&M University.

The hearing will take place Friday, February 12 at 9:00 a.m. in 2123 Rayburn House Office Building, and will be carried live on CSPAN-3. More information about the hearing, including a webcast link, can be found on the Committee website.
 

Upcoming BIO Events 

13th Annual BIO Asia International Conference
March 15-16, 2016
Tokyo, Japan

BIO International Convention
June 6-9, 2016
San Francisco, Calif.

BIO-Europe Spring
April 4-6, 2016
Stockholm, Sweden

 


###

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…